Browse by Medical Category
Not Accepting New Patients
Sekar Kathiresan, MD, is a cardiologist at the Cardiovascular Disease Prevention Center at the Massachusetts General Hospital Heart Center.
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Sekar Kathiresan, a physician scientist and a human geneticist, is the Director of the Center for Genomic Medicine (CGM) at Massachusetts General Hospital (MGH), Ofer and Shelley Nemirovsky MGH Research Scholar, Director of the Cardiovascular Disease Initiative at the Broad institute, and an Associate Professor of Medicine at Harvard Medical School.
Dr. Kathiresan leverages human genetics to understand the root causes of heart attack and to improve preventive cardiac care. Among his scientific contributions, Dr. Kathiresan has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention.
Dr. Kathiresan received his B.A. in history and graduated summa cum laude from the University of Pennsylvania in 1992 and received his M.D. from Harvard Medical School in 1997. He then completed his clinical training in internal medicine and cardiology at MGH, where he served as Chief Resident in Internal Medicine from 2002-2003. Dr. Kathiresan pursued research training in cardiovascular genetics through a combined experience at the Framingham Heart Study and the Broad Institute. In 2008, he joined the faculties of the MGH Cardiology Division, Cardiovascular Research Center, and Center for Genomic Medicine.
View my most recent research
View my most recent publications at PubMed
Research at the MGH is interwoven throughout more than 30 departments, centers and units, and is conducted with the support and guidance of the MGH Research Institute. The Research Roundup is a monthly series highlighting studies, news and events.
A study from Massachusetts General Hospital researchers has found that a pattern of gene variants associated with a body type in which weight is deposited around the abdomen increases the risk for type 2 diabetes and coronary heart disease, as well as the incidence of several cardiovascular risk factors.
With two decades of progress in research-focused discoveries, the field of genomics is now poised to enter a new clinical translation phase, where knowledge of the genome and the molecules it encodes may lead to new diagnostics, predictive tools and treatments. With this new phase, comes a new name: The Center for Genomic Medicine (CGM).
A study led by Massachusetts General Hospital investigators has found that, even among those at high genetic risk for heart disease, following a healthy lifestyle can cut in half the probability of a heart attack or similar event.
The 69th meeting of the MGH Scientific Advisory Committee (SAC), on April 6 and 7, focused on the hospital’s five thematic research centers.
A study from an international research team finds that familial hypercholesterolemia – a genetic condition that causes greatly elevated levels of LDL cholesterol throughout life – accounts for less than 2 percent of severely elevated LDL in the general population but also increases the risk of coronary artery disease significantly more than does elevated LDL alone.
By combing through the DNA of more than 100,000 people, researchers at Broad Institute, Massachusetts General Hospital, and elsewhere have identified rare, protective genetic mutations that lower the levels of LDL cholesterol — the so-called “bad” cholesterol — in the blood.
By scouring the DNA of thousands of patients, researchers have discovered four rare gene mutations that not only lower the levels of triglycerides but also significantly reduce a person’s risk of coronary heart disease
ESTABLISHED IN 2011 by ECOR and the MGH Research Advisory Council, the MGH Research Scholars program provides five years of unrestricted funding to give innovative investigators the flexibility to pursue projects that may lead in unexpected directions. Supported by philanthropic gifts, the program expanded from the first group of five recipients to eight scholars in 2012.
The presentation of the MGH's top research prizes was a highlight of the April 13 Celebration of Science, held in conjunction with the annual Scientific Advisory Committee meeting.
ALL MGHERS are invited to attend the 2011 meeting of the MGH Scientific Advisory Committee (SAC), which will commemorate the hospital’s bicentennial with a look back at significant research accomplishments of MGH investigators and examine challenges facing today’s research community.
An international research collaboration has identified 13 new gene sites associated with the risk of coronary artery disease and validated 10 sites found in previous studies. Several of the novel sites discovered do not appear to relate to known risk factors, suggesting previously unsuspected mechanisms for cardiovascular disease.
Two papers in the current issue of Nature describe 95 gene variations that contribute to cholesterol and triglyceride levels and reveal the unexpected role of a metabolic pathway in lipid metabolism.
An international research team has identified 11 novel locations in the human genome where common variations appear to influence cholesterol or triglyceride levels, bringing the total number of lipid-associated genes to 30.
Sekar Kathiresan, MD, Director of Preventive Cardiology at the Massachusetts General Hospital Heart Center says counteracting your genetic risk is within your control. Learn more about coronary artery disease, who is most at risk and about Mass General's Heart Attack Prevention Program, focused on people with a family history of the disease.
Back to Top